ResMed CEO: Weight-Loss Drugs Aren't Cutting Demand for Sleep Apnea Treatment

Chief Executive Mick Farrell expects the drugs will be used to complement proven treatments.

Related Keywords

California ,United States ,San Diego ,Novo Nordisk Wegovy ,Mick Farrell ,Eli Lilly ,Novo Wegovy ,Chris Ratcliffe Bloomberg ,Lilly Zepbound ,University Of California ,Novo Nordisk ,Executive Mick Farrell ,Atul Malhotra ,Bill Alpert ,Article Normal ,Pharmaceuticals ,Medical Equipment Supplies ,Healthcare Life Sciences ,Financial Performance ,Earnings ,Management ,Corporate Industrial News ,Senior Level Management ,Political General News ,Society Community ,Diabetes ,Episodic Paroxysmal Disorders ,Physical Mental Fitness ,Health ,Sleep Disorders ,Living Lifestyle ,Medical Conditions ,Obesity ,Social Issues ,Weight Management ,Content Types ,Factiva Filters ,C Amp Ampe Industry News Filter ,Synd ,Biotech And Pharma ,Novob Ko ,Dk Novo B ,Rally ,Resmed ,Rmd ,Novo ,Corporate ,Industrial News ,Political ,General News ,Society ,Community ,Episodic ,Paroxysmal Disorders ,Physical ,Mental Fitness ,Living ,Lifestyle ,Medical Equipment ,Supplies ,Healthcare ,Life Sciences ,